FY2024 EPS Forecast for Celldex Therapeutics Cut by Analyst

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Equities research analysts at Leerink Partnrs reduced their FY2024 earnings estimates for shares of Celldex Therapeutics in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will post earnings of ($2.45) per share for the year, down from their previous forecast of ($2.38). The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.50) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics’ Q4 2024 earnings at ($0.71) EPS, FY2025 earnings at ($3.22) EPS, FY2026 earnings at ($4.17) EPS and FY2027 earnings at ($4.12) EPS.

CLDX has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday, November 7th. Finally, The Goldman Sachs Group started coverage on shares of Celldex Therapeutics in a research note on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Trading Up 3.1 %

Shares of NASDAQ:CLDX opened at $27.01 on Monday. The business has a fifty day simple moving average of $33.29 and a 200 day simple moving average of $35.72. Celldex Therapeutics has a 1 year low of $24.43 and a 1 year high of $53.18. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -10.65 and a beta of 1.60.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CLDX. KBC Group NV grew its stake in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Celldex Therapeutics during the 2nd quarter valued at $76,000. Headlands Technologies LLC bought a new stake in Celldex Therapeutics in the 1st quarter valued at $147,000. CANADA LIFE ASSURANCE Co grew its position in Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of Celldex Therapeutics by 34.3% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares during the period.

Insider Transactions at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the business’s stock in a transaction on Monday, November 11th. The stock was purchased at an average price of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.80% of the stock is owned by corporate insiders.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.